Governor Larry Hogan – Official Website of the Governor of Maryland
Annapolis, MD—Governor Larry Hogan today announced that MilliporeSigma, an international biosciences company, is strengthening its presence in Montgomery County with an investment of $286 million to expand its biosafety testing capacity.
The company, known locally as BioReliance Corporation, currently has five locations in Rockville and plans to consolidate into a new 250,000 square foot facility at 9820 Darnestown Road at the Alexandria Center® on the Traville Gateway campus, which is being developed and operated by Alexandria Real Estate Equities, Inc. MilliporeSigma will maintain an additional facility at 9630 Medical Center Drive and retain at least 600 full-time employees during the expansion, while creating more than 500 new jobs over the next four years.
“Maryland has built one of the strongest life sciences industries in the nation, and MilliporeSigma’s reinvestment in its Maryland biosafety facility will bring hundreds of additional jobs to the Montgomery County community and continue to grow the region’s innovative workforce,” Governor Hogan said. “Our administration has made expanding the state’s life sciences and biotechnology research workforce a priority, and the progress made by our life sciences industry over the past eight years is another sign that Maryland is open for business.”
MilliporeSigma is the US and Canadian life sciences business of Merck KGaA, Darmstadt, Germany, a leading science and technology company. This is the largest investment in contract testing in the history of Merck KGaA, Darmstadt, Germany.
MilliporeSigma has been in Maryland for more than 75 years and is expanding its presence in the Mid-Atlantic with Montgomery County’s convenient east coast location and accessibility to highly skilled labor and state technology. Biosafety testing and analytical development are essential and fundamental requirements of the drug development and commercialization process to ensure drug safety.
“Our comprehensive contract testing services center in Rockville will continue to serve as a hub for innovation to meet today’s challenges and meet the demands of tomorrow,” said Benoit Gourdier, contract testing services manager at MilliporeSigma. “We look forward to continuing to grow here and giving back to the Montgomery County community as we transform the lives of patients by ensuring the safety of global medicine.”
To help with the expansion, MilliporeSigma is eligible for a $1 million conditional loan through the Maryland Department of Commerce’s Maryland Advantage Program (MEDAAF). Montgomery County is offering a $100,000 incentive package through a loan-convertible grant as part of its economic development fund. MilliporeSigma is also eligible for various state and local tax credits.
“We are truly grateful for MilliporeSigma’s commitment to doing business in Maryland,” said Maryland Secretary of Commerce Mike Gill. “Building this impressive new space in Rockville ensures the business will continue to thrive in Montgomery County for years to come.”
“We welcome MilliporeSigma’s expansion to Rockville and are proud that the company recognizes that its business can continue to grow significantly here in Montgomery County,” said Montgomery County Executive Marc Elrich. “Their work helps ensure the safety of medicines developed in the county and around the world.”
About the Life Sciences Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, has more than 26,000 employees and more than 55 manufacturing and test sites worldwide, with a portfolio of more than 300,000 scientific discovery products, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates in healthcare, life sciences and electronics. Approximately 60,000 employees work every day to make a positive difference in the lives of millions of people by creating more enjoyable and sustainable lifestyles. From advancing gene-editing technologies, to discovering unique ways to treat the toughest diseases, to enabling device intelligence, the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany achieved sales of €19.7 billion in 66 countries.
The company owns the global rights to the “Merck” name and trademark internationally. The only exceptions are the United States and Canada, where the business segments of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life sciences and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been at the heart of the company’s technological and scientific advancements. To this day, the founding family remains the majority shareholder of the listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.